US5149693A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Combination of tobramycin and fluorometholone for topical ophthalmic use
Assignee: Alcon Research LLC
•
Filing: 1989-11-22
•
Granted: 1992-09-22
•
Expires: 2009-11-22
Abstract
Abstract Disclosed are pharmaceutical compositions comprising tobramycin and fluorometholone or fluorometholone acetate for topical ophthalmic delivery and methods of treatment comprising administering said composition when indicated for infection and control of inflammatory response for optimal wound healing and normalization of the eye.
Inventors
- 👤 Gerald D. Cagle
- 👤 Thomas O. McDonald
- 👤 Allan L. Rosenthal
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 06:08
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
59 words
A method of treating ophthalmic inflammation and infection which comprises administering topically to the affected eye of a human host a therapeutically effective amount of an ophthalmic pharmaceutical composition comprising an anti-inflammatory effective amount of a steroid selected from the group consisting of fluorometholone and fluorometholone acetate; an anti-infective effective amount of tobramycin; and a pharmaceutically acceptable carrier therefor.
Claim 2
Independent Claim
59 words
A method of treating ophthalmic inflammation and infection which comprises administering topically to the affected eye of a human host a therapeutically effective amount of an ophthalmic pharmaceutical composition comprising an anti-inflammatory effective amount of a steroid selected from the group consisting of fluorometholone and fluorometholone acetate; an anti-infective effective amount of tobramycin; and a pharmaceutically acceptable carrier therefor.
Claim 3
Dependent Claim
12 words
A method according to claim 1, wherein the steroid comprises fluorometholone acetate.
Claim 4
Dependent Claim
24 words
A method according to claim 1, wherein the ratio of the tobramycin to the steroid is in the range of from 0.1:1.0 to 10.0:1.0.
Claim 5
Dependent Claim
47 words
A method according to claim 3, wherein the composition is an aqueous solution; the combined concentration of the tobramycin and the steroid is in the range of 0.01 to 2.0 percent by weight; and the pH of the solution is in the range of 4.5 to 8.0.
Claim 6
Dependent Claim
12 words
A method according to claim 4, wherein the steroid comprises fluorometholone acetate.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-09-22 | 1996-03-23 | 1996-09-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-09-22 | 2000-03-23 | 2000-09-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-09-22 | 2004-03-23 | 2004-09-22 | $7700.00 | Window Closed / Lapsed |